Autoimmune Analyzer

A single positive autoimmune test can mean everything or nothing. A positive ANA (antinuclear antibody) screen, for example, appears in up to 25% of healthy women over age 40, depending on the titer threshold used. But when you combine that ANA result with a pattern of specific antibodies targeting particular tissues, along with markers showing how aggressively the immune system is consuming its own defense proteins, the picture sharpens. That is the purpose of this panel: to separate background immune noise from a genuine autoimmune signal.

This panel covers the major antibody targets and immune activity markers used to evaluate lupus, Sjogren syndrome, scleroderma, inflammatory myositis, and rheumatoid arthritis. Ordering these together in a single draw lets you see which direction the immune system is pointing and how much damage it may already be doing.

What This Panel Reveals

The tests in this panel fall into three functional groups: antibodies that flag specific autoimmune diseases, immune proteins that gauge how active the immune attack is right now, and broader screening markers that cast a wider net for autoimmune and inflammatory activity.

Disease-Specific Antibodies

Several antibodies in this panel are tightly linked to particular autoimmune conditions. Antibodies against double-stranded DNA (anti-dsDNA) are found almost exclusively in systemic lupus erythematosus (commonly called lupus, or SLE), with a specificity above 95%, meaning the test is positive almost exclusively in people who actually have the disease. In the 2019 European Alliance of Associations for Rheumatology and American College of Rheumatology (EULAR/ACR) classification criteria for lupus, anti-dsDNA is weighted heavily as a diagnostic indicator.

Antibodies targeting the Smith antigen (anti-Sm) are even more specific for lupus, approaching 99%, though they appear in only about 20% to 30% of people with the disease. When anti-dsDNA and anti-Sm are both present, the probability of lupus is very high.

The panel also includes markers that point toward other connective tissue diseases. Antibodies to SS-A and SS-B are the hallmark of Sjogren syndrome, a condition that causes severe dryness of the eyes and mouth by attacking moisture-producing glands. SS-A antibodies appear in roughly 60% to 70% of people with primary Sjogren syndrome. SS-B antibodies are less common but more specific when present.

The scleroderma antibody (anti-Scl-70, targeting an enzyme called topoisomerase I) is associated with diffuse systemic sclerosis, which causes skin thickening and internal organ scarring. By contrast, antibodies against centromere B point toward limited cutaneous systemic sclerosis, a slower-progressing form that primarily affects the skin of the hands and face. The anti-Jo-1 antibody targets an enzyme involved in protein building and is the signature marker for antisynthetase syndrome, a form of inflammatory muscle disease (myositis) often accompanied by lung involvement.

Immune System Activity Markers

Complement proteins C3 and C4 are part of a cascade your immune system uses to attack invaders. In autoimmune diseases, especially lupus, these proteins get consumed faster than the body can replace them. Low C3 and C4 levels signal that the immune system is actively engaged in an attack. Studies of lupus patients have shown that falling complement levels often precede disease flares by weeks, making them one of the few early warning signals for worsening disease activity.

When complement levels are low at the same time that anti-dsDNA antibodies are elevated, the risk of kidney involvement (lupus nephritis) is significantly higher. This pairing is one of the most actionable patterns in the entire panel.

Broad Screening Markers

The ANA screen is the front door of this panel. Under the 2019 EULAR/ACR criteria, an ANA titer (a measure of antibody concentration, expressed as a ratio like 1:80) of at least 1:80 is the required entry point for even considering a lupus diagnosis. The test is extremely sensitive for lupus (above 95%), meaning a negative ANA makes lupus very unlikely. But a positive ANA alone is not diagnostic of any specific disease.

Rheumatoid factor (RF) detects an antibody that binds to other antibodies, creating clusters called immune complexes that drive joint inflammation. RF is found in about 60% to 80% of people with rheumatoid arthritis, but also appears in 5% to 10% of healthy older adults and in other autoimmune diseases. Its value increases when interpreted alongside the disease-specific markers in this panel.

Anti-TPO (thyroid peroxidase antibody) screens for autoimmune thyroid disease, specifically Hashimoto thyroiditis. Its inclusion reflects an important clinical reality: autoimmune conditions cluster. A person with lupus or Sjogren syndrome has a meaningfully higher risk of also developing autoimmune thyroid disease, a phenomenon called polyautoimmunity. One large study found that thyroid autoimmunity was present in roughly 20% of people with systemic lupus.

How to Read Your Results Together

No single antibody in this panel should be read in isolation. The diagnostic power comes from the pattern. Here are the most clinically significant combinations.

A positive ANA with all specific antibodies negative and normal complement levels is a common result. In most cases, this is a benign finding, especially at lower titers (1:80 or 1:160). Higher titers (1:320 and above) with a homogeneous pattern (smooth, even staining of the cell nucleus) or speckled pattern (dotted staining) warrant closer monitoring even when specific antibodies are currently negative, because autoantibodies can appear months to years before clinical symptoms.

When Results Can Be Misleading

Acute infections can temporarily raise RF levels and even trigger low-positive ANA results. If you are fighting an infection at the time of testing, one or more results may not reflect your baseline immune status. Certain medications, including hydralazine, procainamide, and some anti-seizure drugs, can cause drug-induced lupus with positive ANA and chromatin antibodies. If you take any of these, mention it when interpreting results.

Complement levels can be misleadingly normal in people with mild autoimmune activity, because C3 and C4 are also proteins whose levels naturally rise during any inflammation, meaning inflammation from other causes can push production up and mask consumption. A single normal complement level does not rule out autoimmune activity if antibodies are positive.

Tracking Over Time

This panel becomes substantially more useful with serial measurement. Autoimmune diseases are dynamic. Antibody levels rise and fall with disease activity, and new antibodies can appear as the immune system broadens its targets over time. A person who initially tests positive only for ANA may develop anti-dsDNA or SS-A antibodies months or years later.

For someone with established lupus, tracking anti-dsDNA and complement C3/C4 every three to six months is one of the best ways to detect flares early. Rising anti-dsDNA with falling complement often signals a flare weeks before symptoms appear. For those with an isolated positive ANA and no specific antibodies, repeating the full panel annually can catch the emergence of new autoantibodies before they cause organ damage.

What to Do with Your Results

If every test in this panel is negative, autoimmune disease driven by these specific pathways is unlikely. You can recheck in one to two years if symptoms develop. If the ANA is positive at a low titer (1:80 or 1:160) with all specific antibodies negative and normal complement, no immediate action is needed, but track it annually.

If any disease-specific antibody is positive (anti-dsDNA, anti-Sm, SS-A, SS-B, anti-Scl-70, centromere B, anti-Jo-1, or ribosomal P), consult a rheumatologist regardless of whether you have symptoms. Autoantibodies can appear years before clinical disease, with some detectable more than nine years before diagnosis, and early intervention changes outcomes. If complement levels are low, particularly with concurrent antibody positivity, the urgency increases.

If anti-TPO is elevated with other autoimmune markers positive, add a complete thyroid panel (including Free T3, Free T4, and TSH) to determine whether thyroid function is already affected. If RF is elevated without other markers, consider adding anti-CCP (cyclic citrullinated peptide antibody) to improve specificity for rheumatoid arthritis.